Immunohistochemical expression of EGFR, E-Cadherin, β-Catenin, and Ki67 in dogs with local and invasive cutaneous leiomyosarcoma

Document Type : Research Article

Authors

Fatemeh Heydarzadeh ¹

Amir Amniattalab ²

¹ Department of Clinical Sciences, Faculty of Veterinary Medicine, Ur.C., Islamic Azad University, Urmia, Iran.

² Department of Pathology, Faculty of Veterinary Medicine, Ur.C., Islamic Azad University, Urmia, Iran.

10.22067/ijvst.2025.93754.1557

Abstract

Cutaneous leiomyosarcoma (LMS) is a rare malignant smooth muscle tumor in dogs and humans, potentially arising from smooth muscle fibers of hair follicles, blood vessels, or genital tissues. This study examined the prevalence, clinicopathological features, hematological changes, and immunohistochemical characteristics of canine cutaneous LMS. Over a 10-year period in Urmia, Iran, six cases (three local and three invasive) of cutaneous leiomyosarcoma (LMS) were identified among 318 dogs presenting with cutaneous lesions representing a prevalence of 1.88%. The hematological analysis indicated significant leukocytosis, monocytosis, and eosinophilia in the affected dogs (p < 0.05) compared to the healthy dogs. Microscopically, a range of cellular pleomorphism and neoplastic smooth muscle fibers in interlacing bundles with scant stromal connective tissue were observed. Immunohistochemistry (negative for MyoD1, Myogenin, and CD31) confirmed piloleiomyosarcoma. A significant increase (p < 0.05) was observed in positive expression and H-score for Desmin, SMA, Vimentin, and Ki67 markers. EGFR and β-Catenin expression was significantly increased in the localized LMS group (p < 0.05) compared to invasive LMS and normal tissue, whereas E-Cadherin expression showed no significant difference in LMS cases. These findings indicate that EGFR is not limited to epithelial tumors but is also expressed in mesenchymal tumors like LMS. The reduction in invasive LMS cases suggests EGFR upregulation may precede metastasis. Although E-Cadherin/β-Catenin expression alone may be insufficient for prognosis, their combined evaluation with proliferative and mesenchymal markers could provide valuable insight into invasion pathways and aid in developing targeted therapies against invasive tumors.
 

Keywords

Cutaneous leiomyosarcoma

Dog

Immunohistochemistry

Intercellular adhesion

Proliferation

Subjects

• Pathology

---

References

1.     Torrigiani F, Pierini A, Lowe R, Simčič P, Lubas G. Soft tissue sarcoma in dogs: A treatment review and a novel approach using electrochemotherapy in a case series. Vet Comp Oncol. 2019;17(3):234–41. Doi:10.1111/vco.12462.
2.     Guisado FR, Castro PL. Piloleiomyosarcoma in cats: Histological and immunohistochemical features. Vet Pathol. 2022;59(1):57–62. Doi:10.1177/03009858211042582. 
3.     Aihara N, Sugiyama J, Baba H, Kamiie J. Multiple cutaneous pleomorphic leiomyosarcoma in a dog. J Vet Med Sci. 2019;81(11):1564–6. Doi:10.1292/jvms.19-0295.
4.     Kim YJ, Jeon Y, Bae H, Shin SW, Cho Ar, Hyun J-E, et al. Oral leiomyosarcoma in a dog. J Biomed Transl Res. 2021;22(4):199–204. Doi:10.12729/jbtr.2021.22.4.199.
5.     Han J, Kim Y, Kim D, Na K. Alteration in E-Cadherin/b-Catenin expression in canine melanotic tumors. Vet Pathol. 2012;50(2):274–80. Doi:10.1177/0300985812457792.
6.     Bongiovanni L, Malatesta D, Brachelente C, D’Egidio S, Della Salda L. β-Catenin in canine skin: Immunohistochemical pattern of expression in normal skin and cutaneous epithelial tumours. J Comp Pathol. 2011;145(2–3):138–47. Doi:10.1016/j.jcpa.2011.01.008.
7.     Files R, Santos C, Queiroga FL, Silva F, Delgado L, Pires I, et al. Investigating Cox-2 and EGFR as biomarkers in canine oral squamous cell carcinoma: Implications for diagnosis and therapy. Curr Issues Mol Biol. 2024;46:485–497. Doi:10.3390/cimb46010031.
8.     Jung J-Y, Kang S-C, Park D-S, Lee E-S, Bae J-H, Kim J-H. Cutaneous smooth muscle tumors in 3 dogs. Korean J Vet Res. 2009;49(1):63–6. 
9.     Martins AL, Canadas‑Sousa A, Mesquita JR, Dias‑Pereir P, Amorim I, Gärtner F. Retrospective study of canine cutaneous tumors submitted to a diagnostic pathology laboratory in Northern Portugal (2014–2020). Canine Med Genet. 2022;9(1):2. Doi:10.1186/s40575-022-00113-w.
10.     Jacobs TM, Poehlmann CE, Kiupel M. Injection-site sarcoma in a dog: clinical and pathological findings. Case Reports Vet Med. 2017;2017:1–4. Doi:10.1016/j.tips.2003.09.006.
11.     Kapatkin AS, Mullen HS, Matthiesen DT, Patnaik AK. Leiomyosarcoma in dogs: 44 cases (1983-1988). JAVMA. 1992;201(7):1077–9. 
12.     Meuten DJ. Tumors in Domestic Animals. Fifth. Wiley Blackwell; 2017. 15–16 p. 
13.     Avallone G, Pellegrino V, Muscatello LV, Roccabianca P, Castellani G, Sala C, et al. Canine smooth muscle tumors: A clinicopathological study. Vet Pathol. 2022;59(2):244–55. Doi: 10.1177/03009858211066862.
14.     Berr AL, Wiese K, Santos G dos, Koch CM, Anekalla KR, Kidd M, et al. Vimentin is required for tumor progression and metastasis in a mouse model of non–small cell lung cancer. Oncogene. 2023;42:2074–8. Doi: 10.1038/s41388-023-02703-9.
15.     Yim IS, Laronde DM. Biomarkers of epithelial-mesenchymal transition: E-cadherin and beta-catenin in  malignant transformation of oral lesions. Can J Dent Hyg  CJDH = J Can l’hygiene  Dent  JCHD. 2024;58(2):111–9. 
16.     Ciaputa R, Brambilla E, Godizzi F, Dzimira S, Żebrowski K, Kandefer-Gola M, et al. First report of primary testicular leiomyosarcoma in two dogs. BMC Vet Res. 2023;19:101. Doi: 10.1186/s12917-023-03658-5.
17.     Brady R V., Rebhun RB, Skorupski KA, Burton JH, Al-Nadaf S, Choi E, et al. Retrospective immunohistochemical investigation of suspected non-visceral leiomyosarcoma in dogs. J Vet Diagnostic Investig. 2022;34(3):465–73. Doi:10.1177/10406387221083570.
18.     Sette G, Salvati V, Memeo L, Fecchi K, Colarossi C, Di PM, et al. EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential. PLoS One. 2012;7(10):e46891. Doi:10.1371/journal.pone.0046891.
19.     Sasaki T, Hiroki K, Yamashita Y. The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment. Biomed Res Int. 2013;2013:1–8. Doi:10.1155/2013/546318. 
20.     Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG. Expression of E-cadherin, ß-catenin and topoisomerase IIα in leiomyosarcomas. Clin Transl Oncol. 2009;11:548–51. Doi:10.1007/s12094-009-0401-3.
21.     Sanz Ressel B, Massone A, Barbeito C. Aberrant expression of E-cadherin/b-catenin during epidermal tumourigenesis in dogs. J Comp Pathol. 2020;176:1–9. Doi:10.1016/j.jcpa.2020.01.006.
22.     Debruyne P, Vermeulen S, Mareel M. The role of the E-cadherin/catenin complex in gastrointestinal cancer. Acta Gastroenterol Belg. 1999;62:293–402. 
23.     Firsching TC, Dietert K, Bartel A, Gruber MGD, D A. Dependence of the Ki67 Labelling Index of Selected Canine Tumours on Patient Age, Sex and Tumour Size. J Comp Pathol. 2022;193:1–8. Doi:10.1016/j.jcpa.2022.02.001.
24.     Travaglino A, Raffone A, Catena U, Luca M De, Toscano P, Prete E Del, et al. Ki67 as a prognostic marker in uterine leiomyosarcoma: A quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2021;261:119–24. Doi:10.1016/j.ejogrb.2021.09.026. 
25.     Bergin IL, Smedley RC, Esplin DG, Spangler WL, Kiupel M. Prognostic Evaluation of Ki67 Threshold Value in Canine Oral Melanoma. Vet Pathol. 2011;48(1):41–53. Doi:10.1177/0300985810388947.
26.     Adegboyega PA, Qiu S. Immunohistochemical profiling of cytokeratin expression by endometrial stroma sarcoma. Hum Pathol. 2008;39:1459–64. Doi:10.1016/j.humpath.2008.02.008.
27.     Amoorahim S, Amniattalab A. Immunohistochemical expression of GDNF, P53 and Ki67 with Tunel assay in canine non-neoplastic esophageal nodules induced by Spirocerca lupi. Maced Vet Rev. 2025;48(1):39–51. Doi:10.2478/macvetrev-2025-0014.
28.     Babanezhad-gajouti A, Amniattalab A. in the canine spleen with siderofibrotic nodules : an immunohistochemical and immunofluorescence perspective on apoptosis , ferroptosis , and oxidative stress. Turkish J Vet Anim Sci. 2023;47(4):397–412. Doi:10.55730/1300-0128.4308. 
29.     Piercealla WE, Wolfea M, Suschaka J, Changa H, Chena Y, Sprotta KM, et al. Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic response diagnostics. Anal Cell Pathol. 2011;34:159–68. Doi:10.3233/ACP-2011-014. 
30.     Ruengwanichayakun P. Histochemical scoring assessment (H-score). Asian Arch Pathol. 2021;3(1):13–4.